[ACCESSWIRE]
NEW YORK, NY / ACCESSWIRE / August 6, 2015 / Xenetic Biosciences, Inc. (OTCQB: XBIO) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Scott Maguire, MBA. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In his inaugural blog, Scott Maguire discusses Xenetic's promising novel drug developments and partnerships with leading world healthcare companies such as Baxter International (NYSE: BAX). He expands on the progress of the Company's main initiatives PolyXen(R), OncoHist(TM), and ErepoXen(R) and shares Company goals moving forward. Read the full blog post from Mr. Maguire on TheChairmansBlog.com (http://www.thechairmansblog.com/xenetic-biosciences/scott-maguire/why-global-healthcare-companies-have-invested-in-xenetic-biosciences/).
About Xenetic Biosciences
Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen(R), designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs, and OncoHist(R) for the development of novel oncology drugs focused on orphan indications.
Xenetic's lead product candidates include ErepoXen(R), a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and OncoHist(R), a novel recombinant human histone H1.3 molecule for the treatment of refractory Acute Myeloid Leukemia (AML) with potential to treat numerous other cancer indications. Xenetic is collaborating with Russian-based OJSC Pharmsynthez (who is an affiliate of a significant shareholder in Xenetic) and the Serum Institute of India to test additional drug and vaccine candidates and to de-risk the development process with clinical data generated in Russia and India before Xenetic takes these candidates into the clinic in the Western markets.
Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at www.xeneticbio.com.
Baxter Healthcare:
Xenetic is working together with Baxter International Inc. to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on the PolyXen technology to conjugate PSA to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Baxter is one of the Company's largest shareholders having invested in a number of rounds with the most recent investment of $10M last year. The agreement is exclusive research, development and license agreement grants Baxter a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary technology in combination with Baxter's proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target receipts for total potential milestones of up to $100 million plus royalties on sales.
About TheChairmansBlog.com
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com
SOURCE: TheChairmansBlog.com
